Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00025974 · ClinicalTrials.gov registry record

Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder

A clinical trial, sponsored by National Institute of Mental Health (NIMH).

Completed
Registry status
230
Enrollment target

NCT00025974: Completed study, sponsored by National Institute of Mental Health (NIMH).

NCT00025974 is a clinical trial that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 230 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00025974 has completed, sponsored by National Institute of Mental Health (NIMH).

COMPLETED
Registry status
230 participants
Enrollment target

Study Summary

The purpose of this study is to examine how certain brain chemicals work in patients with Panic Disorder (PD) and Post-Traumatic Stress Disorder (PTSD) with and without major depressive disorder (MDD). Brain chemicals that regulate emotion, anxiety, sleep, stress hormones, and other body functions bind to serotonin (5-HT1A) and benzodiazepine (BZD) receptors. Evidence suggests that 5-HT1A and BZD receptor function is abnormal in patients with PD, PTSD, and depression. This study will use positron emission tomography (PET) scans to examine BZD and 5-HT1A receptor binding potential in patients with PD and patients with PTSD with and without co-morbid MDD, as well as in healthy volunteers. This study will also determine the effects of the stress hormone cortisol on 5-HT1A and BZD receptors. The current emotional state and psychiatric, medical, and family history of potential participants will be evaluated during an initial telephone interview. After entering the study, participants will be asked questions about general mood, degree of nervousness, and behavior. A physical examination, an electrocardiogram (EKG), and tests of intelligence and cognition will be given. Urine, blood, and saliva samples will be taken. Women will be given pregnancy tests and tests to determine menstrual phase and time of ovulation. All volunteers will undergo magnetic resonance imaging (MRI) and PET scans of the brain. ...

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2001-10-31
Est. Completion 2008-07-21

What the finished NCT00025974 record still lists

NCT00025974 is an observational study that tracks outcomes without assigning an intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00025974 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00025974 about?

NCT00025974 is a clinical study titled "Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder". The purpose of this study is to examine how certain brain chemicals work in patients with Panic Disorder (PD) and Post-Traumatic Stress Disorder (PTSD) with and without major depressive disorder (MDD). Brain chemicals that regulate emotion, anxiety, sleep, stress hormones, and other body functions ...

What is the current status of trial NCT00025974?

This trial is currently completed. The enrollment target is 230 participants. The study started on 2001-10-31. Estimated completion is 2008-07-21.

Who is sponsoring clinical trial NCT00025974?

This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02710253 · 230 participants · Phase 2

    Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

  • NCT02777879 · 230 participants

    Lung Microbiome and Inflammation in Early COPD

  • NCT03824483 · 230 participants · Phase 2

    Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

  • NCT03833622 · 230 participants · NA

    Shared Decision Making to Improve Goals of Care in the ED

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00025974, the US trial registry maintained by the National Library of Medicine. NCT00025974 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.